安徽丰原药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，本公司收到国家药品监督管理局核准签发的复方醋酸钠林格注射液 （250ml）《药品注册证书》（证书编号：2026S00519）及复方醋酸钠林格注射液(500ml) 《药品注册证书》（证书编号：2026S00518）。现将相关情况公告如下： 一、药品注册证书的主要内容 | 1、复方醋酸钠林格注射液（250ml） | | --- | 股票简称：丰原药业 股票代码：000153 公告编号：2026—003 | 2、复方醋酸钠林格注射液(500ml） | | --- | | 药品名称 | 药品通用名称：复方醋酸钠林格注射液 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 英文名/拉丁名：Compound Sodium Acetate | | | | | Ringer's | Injection | | | 主要成份 | 本品为复方制剂，组分包括氯化钠、氯化钾、氯 ...

Group 1 - The core viewpoint of the article is that Fengyuan Pharmaceutical has established a contract manufacturing partnership with Marubeni Pharmaceutical to enhance production capacity utilization [1] - According to the cooperation agreement, Fengyuan Pharmaceutical will manufacture Marubeni Pharmaceutical's Acetate Lofexidine Injection Diluent, while Marubeni Pharmaceutical will handle sales coverage and customer maintenance for the contract products [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., has completed a self-examination of tax matters and is required to pay a total of 16.56 million yuan in tax and late fees, which has been fully paid as of the announcement date [1]. Group 1: Basic Information - The total amount of tax and late fees to be paid is 16.56 million yuan, consisting of 11.23 million yuan in tax and 5.33 million yuan in late fees [1]. - The payment of the aforementioned tax and late fees has been completed as of the date of the announcement [1]. Group 2: Impact on the Company - According to relevant regulations, the payment of tax and late fees does not constitute a prior accounting error and will not involve retrospective adjustments to previous financial data [1]. - The tax payment will be included in the company's profit and loss for the year 2025, with the specific impact on net profit attributable to shareholders to be determined based on the audit data from the accounting firm [1]. - This tax payment matter will not affect the normal operations of the company [1].

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., is required to pay a total of 16.56 million yuan in tax and late fees, which includes 11.23 million yuan in tax and 5.33 million yuan in late fees. As of the date of this announcement, all amounts have been paid in full [1]. Group 1 - The total amount required for tax and late fees is 16.56 million yuan [1]. - The breakdown of the payment includes 11.23 million yuan in tax and 5.33 million yuan in late fees [1]. - The company has confirmed that all payments have been completed as of the announcement date [1].

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., is required to pay a total of 16.56 million yuan in tax and late fees, which includes 11.23 million yuan in tax and 5.33 million yuan in late fees. As of the date of this announcement, all tax and late fees have been fully paid [1]. Group 1 - The total amount required for tax and late fees is 16.56 million yuan [1] - The breakdown includes 11.23 million yuan in tax and 5.33 million yuan in late fees [1] - All payments have been completed as of the announcement date [1]

股票简称：丰原药业 股票代码：000153 公告编号：2026-002 安徽丰原药业股份有限公司 关于公司补缴税款的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）全资子公司蚌埠丰原涂山制药有限 公司近期依据国家税收法律法规的要求，对涉税事项开展自查，现将有关事项公告 如下： 一、基本情况 经自查，公司全资子公司蚌埠丰原涂山制药有限公司应补缴税款及滞纳金合计 1,656.09 万元，其中：补缴税款 1,122.77 万元，滞纳金 533.32 万元。截至本公告披 露日，上述税款及滞纳金已全部缴纳。 二、对公司的影响及风险提示 根据《企业会计准则第 28 号--会计政策、会计估计变更和差错更正》相关规定， 上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追溯调整。 上述补缴税款及滞纳金将计入公司 2025 年当期损益，对公司 2025 年度归属于上市 公司股东的净利润的具体影响金额最终以会计师事务所审计数据为准。本次补缴税 款事项不会影响公司的正常经营，敬请广大投资者注意投资风险。 特此公告。 安徽丰原药 ...

Group 1 - The company has completed the capital increase to Hongfeng Fund as of January 20 [2] - The company will fulfill its information disclosure obligations regarding the subsequent situation of Hongfeng Fund as required [2]

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. has completed the repurchase and cancellation of a portion of restricted stocks, resulting in a decrease in total share capital by 88,200 shares, which is 0.0190% of the total share capital before the repurchase [2][11]. Group 1: Repurchase and Cancellation Details - The repurchase involved 3 incentive targets, with a total of 88,200 shares being repurchased at a price of 2.67 yuan per share, amounting to a total payment of 246,091.23 yuan [2][10]. - The repurchase was completed on January 9, 2026, reducing the company's total share capital from 464,773,722 shares to 464,685,522 shares [2][11]. Group 2: Background of the Stock Incentive Plan - The stock incentive plan was approved during the board meeting on August 12, 2022, with independent directors providing opinions on its benefits for the company's sustainable development [3]. - The plan included a public announcement of the incentive targets from August 15 to August 24, 2022, with no objections received [4]. - The first grant of restricted stocks was approved on September 23, 2022, with 19,970,000 shares granted at a price of 4.13 yuan per share [5]. Group 3: Reasons for Repurchase - The repurchase was necessitated by one incentive target leaving the company and two others failing to meet performance criteria, leading to the cancellation of 33,600 shares and 54,600 shares, respectively [9].

Group 1 - The company announced a repurchase and cancellation of restricted stocks involving 3 incentive recipients, totaling 88,200 shares, which accounts for 0.0190% of the company's total share capital before the repurchase [2] - The repurchase price for the restricted stocks was set at 2.67 yuan per share, leading to a total payment of 246,091.23 yuan for the repurchase [2] - Following the completion of the repurchase and cancellation, the company's total share capital decreased from 464,773,722 shares to 464,685,522 shares [2]

股票简称：丰原药业 股票代码：000153 公告编号：2026-001 安徽丰原药业股份有限公司关于回购 注销部分限制性股票完成暨股本变动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 特别提示： 1、安徽丰原药业股份有限公司（以下简称公司）本次回购注销的限制性股票涉及激励对象 人数 3 人，回购注销的股票数量合计 88,200 股，占回购前公司总股本的 0.0190%。 1 2022 年限制性股票激励计划（草案）>及摘要的议案》、《关于<公司 2022 年限制 性股票激励计划实施考核管理办法>的议案》、《关于提请股东大会授权董事会办理 公司 2022 年限制性股票激励计划有关事项的议案》。2022 年 9 月 9 日在巨潮资讯网 披露《2022 年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的 自查报告》（公告编号：2022-036）。 2、本次回购的限制性股票回购价格为 2.67 元/股。公司应就本次限制性股票回购支付回购 款项合计 246,091.23 元。 3、公司于 2026 年 1 月 9 日在中国证券登记结算有限责任公司深圳分 ...